Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption

Cited 69 time in webofscience Cited 0 time in scopus
  • Hit : 707
  • Download : 51
Current antiangiogenic therapy is limited by its cytostatic nature and systemic side effects. To address these limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progression. RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling pathway in tumor endothelial cells, consequently resulting in a functional failure Of tumor vasculatures. Moreover, enhanced anticancer effects were observed when RhoJ blockade was employed in concert with a cytotoxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent. These results identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature with minimal side effects.
Publisher
CELL PRESS
Issue Date
2014-01
Language
English
Article Type
Article
Citation

CANCER CELL, v.25, no.1, pp.102 - 117

ISSN
1535-6108
DOI
10.1016/j.ccr.2013.12.010
URI
http://hdl.handle.net/10203/189715
Appears in Collection
BS-Journal Papers(저널논문)BiS-Journal Papers(저널논문)MSE-Journal Papers(저널논문)
Files in This Item
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 69 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0